会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 17. 发明申请
    • TIN FOR FOODSTUFFS
    • 罐身
    • WO1997020741A1
    • 1997-06-12
    • PCT/EP1996005414
    • 1996-12-04
    • SCHMALBACH-LUBECA AGPETER, WolfgangHARTUNG, HansBECKER, Horst
    • SCHMALBACH-LUBECA AG
    • B65D01/40
    • B65D1/12B65D1/165
    • The invention concerns a tin for foodstuffs, the tin comprising a base (10) and a peripheral wall (20) which projects from the base and surrounds an inner space (30). The upper edge of the wall delimits all around an opening (31) in the inner space (30), the inner space (30) widening conically upwards and the wall (20), which surrounds this inner space, merging at the bottom into the base (10) at a rounded portion (21). The merging region is designed such that a peripheral annular bearing line (11) is produced but, on the interior, the base is first further extended upwards and then a bearing surface (16) between 1.5 and 10 mm wide is produced by a downwardly projecting peripheral annular bead (15).
    • 罐体具有围绕底部(10)和从其直立的,内部空间(30),连续的侧壁(20)。 侧壁以其上边缘限定的内部(30)的开口(31)周围,由此感知空间(30)变宽锥形向上和它(在舍入周围下面侧壁(20)的地(21)10 )通过。 这种转变被设计为使得一个环绕的环形阀座型线(11)形成,所述底部,但是,进一步向内延伸最初向上,但随后有一个向下突出的圆周的环形卷边(15)具有的宽度的支承面(16) 1.5至10mm被产生。
    • 18. 发明申请
    • EXTERNALLY CONTROLLED APPLICATION OF COMPOUND IN EDGES OF CANS
    • 罐装SHELVES合物的外资控制应用
    • WO1997005975A1
    • 1997-02-20
    • PCT/DE1996001459
    • 1996-08-05
    • SCHMALBACH-LUBECA AGPETER, WolfgangHARTUNG, HansPOZAS, Jesus, Diez
    • SCHMALBACH-LUBECA AG
    • B21D51/26
    • B29C31/042B29C43/18B29C43/34B29C2043/3433B29K2105/0002B29L2031/56B29L2031/565
    • A process and device are disclosed for uniformly applying fluid sealing material (compound;C,R) in the body or cover hook (81;81i,81n,81r) of a lid (D) in order to prepare a tight double seam closure. A plurality of needles (30a,30b,30c,...;30x) or a continuous projecting ring (37,38) enter with their front ends (35a,35b,35c,...;35x,38) through one or several bottom openings (40;40x) in a continuous application channel (48) with two delimiting edges (45b,46b). The axial position of the needles (30x) or projecting ring (37,38) in the channel (48) may be adjusted from behind (31a,32a,...;31x,32x) without their ends (35a,...,35x,38) at the channel side having to absorb axial adjusting forces from the body or cover hook (81n). The compound (fluid sealing material) may thus be more precisely, more uniformly and more gently applied on the body or cover hook, and damages to the metallic application point are avoided, in particular in the case of metal sheets of less than 0.24 mm thickness. Although the compound is applied more gently, it is precisely dosed and positioned, so that the resulting sealing ring (R) has exactly the width, thickness and position required in the cover or body hook to ensure the tightness of the double seam closure formed therefrom. The amount of sealing material (C) used can also be reduced.
    • 的方法和用于流体密封材料的均匀应用的装置,提出了(“化合物” C,R)中的主体钩或盖钩(81; 81I,81N,81R)的盖子(D)中,以制备紧双重接缝。 多个针(30A,30B,30C,...; 30X)设置或环绕的环形腹板(37,38),其与它的前端(35A,35B,35C,...; 35倍; 38)由 一个或多个底部开口(一个或多个)(40; 40倍)延伸在圆周应用信道(48)(,46b的45B)具有两个边缘腹板限制它。 针(30倍),或从后环杆(37,38)的(31A,32A,...; 31X,32X)前在通道(48)而没有它们的信道侧的端部的轴向位置可调(35A ,. ..,35倍; 38)的轴向从主体钩或从盖钩调节力(81N)接收。 这确保应用化合物(流体密封材料)精确,均匀的和温和的主体钩或端盖钩连部,以防止特别是在低温的厚度小于0点24毫米的金属涂层位置的损伤。 虽然是要温柔本发明,顺序,它被计量和位置更准确,从而使所得到的密封环(R)是在所述盖钩或本体钩连部的宽度,厚度和位置非常精确,以保证从它形成的Doppelfalzverschlusses的紧密性,并且还 密封剂(C)进行保存。
    • 19. 发明申请
    • MIRNA BASED TREATMENT MONITORING IN MULTIPLE SCLEROSIS
    • MIRNA治疗多发性硬化的疗效观察
    • WO2013131567A1
    • 2013-09-12
    • PCT/EP2012/053944
    • 2012-03-07
    • FEBIT HOLDING GMBHKELLER, AndreasBEIER, MarkusSCHEFFLER, MatthiasWENDSCHLAG, AnkeAKTAS, OrhanINGWERSEN, JensHARTUNG, Hans-PeterKÜRY, PatrickPROZOROVSKI, Timour
    • KELLER, AndreasBEIER, MarkusSCHEFFLER, MatthiasWENDSCHLAG, AnkeAKTAS, OrhanINGWERSEN, JensHARTUNG, Hans-PeterKÜRY, PatrickPROZOROVSKI, Timour
    • C12Q1/68
    • C12Q1/6883C07K16/2842C12Q2600/106C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/178
    • The present invention relates to methods of determining whether a patient responds to a therapeutic treatment of multiple sclerosis (MS), of monitoring the course of multiple sclerosis (MS) in a patient, of determining the risk for a relapse of multiple sclerosis (MS) in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient. Said methods are based on the determination of the level of at least one miRNA in a test sample isolated from the patient. The present invention also relates to a method of identifying a compound suitable for the treatment of multiple sclerosis in a patient. Further, the present invention relates to the use of a polynucleotide or a polynucleotide set for detecting a miRNA to determine whether a patient responds to a therapeutic treatment of multiple sclerosis, to monitor the course of multiple sclerosis in a patient, to determine the risk of a relapse of multiple sclerosis in a patient, to adjust the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, and to identify a compound suitable for the treatment of multiple sclerosis in a patient. Furthermore, the present invention relates to a kit for determining whether a patient responds to a therapeutic treatment of multiple sclerosis, for monitoring the course of multiple sclerosis in a patient, for determining the risk of a relapse of multiple sclerosis in a patient, for adjusting the dose of a therapeutic drug applied for therapeutic treatment of multiple sclerosis in a patient, or for identifying a compound suitable for the treatment of multiple sclerosis in a patient comprising means for determining the level of at least one miRNA in a test sample isolated from a patient.
    • 本发明涉及确定患者是否对多发性硬化症(MS)的治疗性处理作出反应,监测患者中多发性硬化症(MS)的过程,确定患者 患者中多发性硬化症(MS)的复发以及调整应用于患者中多发性硬化症的治疗性治疗的治疗药物的剂量。 所述方法基于确定从患者分离的测试样品中的至少一种miRNA的水平。 本发明还涉及鉴定适合于治疗患者多发性硬化症的化合物的方法。 此外,本发明涉及用于检测miRNA的多核苷酸或多聚核苷酸的用途,以确定患者是否对多发性硬化症的治疗性处理作出反应,监测患者中多发性硬化的进程,以确定 患者中多发性硬化症的复发,调整应用于患者中多发性硬化症的治疗性治疗的治疗药物的剂量,以及鉴定适合于治疗患者中多发性硬化症的化合物。 此外,本发明涉及用于确定患者是否对多发性硬化症的治疗性处理作出反应,用于监测患者中多发性硬化症的过程,用于确定患者中多发性硬化症复发的风险的试剂盒,用于调整 用于治疗性治疗患者中多发性硬化症的治疗药物的剂量,或用于鉴定适合于治疗患者中多发性硬化症的化合物的剂量,所述方法包括用于确定从患者的多发性硬化症分离的测试样品中的至少一种miRNA的水平的工具 患者